`
`
`
`x CJ cologuard’
`6 Lo-your diet or medication. Peagke can collect miple iin Lhe pei
`
`
`
`strong scienceand rabsusl clini
`Backed by
`
`collaborationwith Mayo Clinic, Cologuard!isastocl DNA-based
`colorecial cancer screening lest for average-risk individuals whe
`are 45 or older. Cologuard wes a biomarker paned whichanalyoes
`
`8 person's stool sample for 10 ONA markers, a well as blood jin the
`
`stool(hermoglobin). This multi-marker approachisa
`distinguishing
`feature of Exact Sciences’ scientific platforen.
`Cologuard finds colon cancer evenin early stages wieniL is more
`22
`resentsBoles!
`
`a noninvasive screening optionUl
`Cologuard is convenient.I's
`can be used at hone Lhal requires mo special prep, no need for
`
`Lime off, ne chang
`
` acy of their ownhore,
`Uheir Cologuard :
`
` patient navigation programwith
`bualt-ir
`Cologuard inclucte
`
`nd reminder texts ane calls to
`24/7 patient support for questions
`support completionofthe lest.
`
`
`
`INNOVATION SUPPORTS THE COLOGUARD
`
`SCIENTIFIC PLATFORM
`
`eo
`
`,
`
`“™
`
`STOOL DNAISOLATION
`
`@®ooss
`
`Geneoscopy Exhibit 1079, Page 1
`
`Geneoscopy Exhibit 1079, Page 1
`
`
`
`SCIENCES
`
`About
`
`Newsroom
`
`Our Tests
`
`Pipeline & Data
`
`Investor Relations
`
`Join Our Team
`i
`
`x CJcologuard’
`
`
`Backed by strong science and robustclinical research in
`collaboration with Mayo Clinic, Cologuard® is a stool DNA-based
`colorectal cancer screening test for average-risk individuals who
`are 45 or older. Cologuard uses a biomarker panel which analyzes
`a person's stool sample for 10 DNA markers, as well as blood in tne
`stool (hemoglobin). This multi-marker approachis a distinguishing
`feature of Exact Sciences’ scientific platform.
`
`Cologuard finds colon cancer even in early stages whenit is more
`treatable!2"
`
`Cologuard is convenient.It’s a noninvasive screening option that
`can be used at home that requires no special prep, no need for
`time off, no changes to your diet or medication. People can collect
`their Cologuard sample in the privacy of their own home.
`Cologuard includes a built-in patient navigation program with
`24/7 patient support for questions and reminder texts and calls to
`support completion of the test.
`
`eeees)Re
`
`ees1bhee) 0)
`
`INNOVATION SUPPORTS THE COLOGUARD
`
`GeneoscopyExhibit 1079, Page 2
`
`Geneoscopy Exhibit 1079, Page 2
`
`
`
`INNOVATION SUPPORTS THE COLOGUARD
`
`SCIENTIFIC PLATFORM
`
` DNASTABILITY TECHNOLOGY
`®
`
`Q
`
`DNA BIOMARKER DETECTION
`
`©
`
`HEMOGLOBIN BIOMARKER
`DETECTION AND STABILITY
`TECHNOLOGY
`
`POWERFUL MATHEMATICAL
`ALGORITHM
`
`STOOL DNAISOLATION
`
`This proprietary technology proved to be a breakthrough in the
`development of the multitarget stool DNA test. Our scientists
`needed to first solve the essential problem of effectively
`isolating DNA from stool before achieving the goal of
`
`developing a noninvasivecolon cancerscreening test.
`
`}
`
`@®ooo oa
`
`
`
`“Based on 5-year relative survival
`
`Geneoscopy Exhibit 1079, Page 3
`
`Geneoscopy Exhibit 1079, Page 3
`
`
`
`INNOVATION SUPPORTS THE COLOGUARD
`
`SCIENTIFIC PLATFORM
`
`a @
` STOOL DNA ISOLATION
`
`DNA BIOMARKER DETECTION
`
`HEMOGLOBIN BIOMARKER
`DETECTION AND STABILITY
`TECHNOLOGY
`
`POWERFUL MATHEMATICAL
`ALGORITHM
`
`TECHNOLOGY
`
`DNA STABILITY
`
`The development of an enhanced DNA stabilizing buffer was a
`critical step in the process of creating a reliable at-horne
`screening kit. With this advance, the DNA in stool samplesis
`protected throughthe transport process and remains amenable
`
`to analysisonceitarrivesatour processing center.
`
`>)
`
`Oo @0 0 0
`
`Geneoscopy Exhibit 1079, Page 4
`
`Geneoscopy Exhibit 1079, Page 4
`
`
`
`INNOVATION SUPPORTS THE COLOGUARD
`
`SCIENTIFIC PLATFORM
`
`®o
`
`STOOL DNA ISOLATION
`
`® Ss ©
`
`DNA, STABILITY TECHNOLOGY
`
`
`
`HEMOGLOBIN BIOMARKER
`DETECTION AND STABILITY
`TECHNOLOGY
`
`POWERFUL MATHEMATICAL
`ALGORITHM
`
`human DNA in each sample.
`
`We developed our proprietary QUARTS technology (Quantitative
`Allele-specitic Real-time Target and Signal Amplification) which
`efficiently amplifies and quantifies two separate methylated
`DNA markers (NDRG4 and BMP3) along with seven distinct
`
`KRASgene point mutations. The beta actin (ACTB) geneserves
`
`as a reference markerfor quantitation of the total amount of
`
`>)
`
`DNA BIOMARKER
`DETECTION
`
`Oo 08 0 0
`
`Geneoscopy Exhibit 1079, Page 5
`
`Geneoscopy Exhibit 1079, Page 5
`
`
`
`INNOVATION SUPPORTS THE COLOGUARD
`
`SCIENTIFIC PLATFORM
`
`STOOL DNA ISOLATION
`
`DNASTABILITY TECHNOLOGY
`
`DNA BIOMARKER DETECTION
`
`HEMO POWERFUL MATHEMATICAL
`ALGORITHM
`
`
`TECHNOLOGY
`
`HEMOGLOBIN BIOMARKER
`
`aioeiartet Riag
`
`Weimproved upon the technology for the ELISA-based
`detection of a protein biomarker (hernoglabin) through an
`additive in the stabilization buffer. This innovation allows for
`longer transit time from sample collection to processing by the
`
`“
`
`©)
`
`oO 0.0 @ 80
`
`Geneoscopy Exhibit 1079, Page 6
`
`Geneoscopy Exhibit 1079, Page 6
`
`
`
`INNOVATION SUPPORTS THE COLOGUARD
`
`SCIENTIFIC PLATFORM
`
`TECHNOLOGY
`
`HEMOGLOBIN BIOMARKER
`DETECTION AND STABILITY
`
`POWE
`
`Thefinal step in the multitarget stool DNA test incorporates the
`quantitative results from the DNAalterations combined with the
`protein biomarker detection to determine a positive or negative
`result. This algorithm is the vital workhorse that translates our
`invisible biology into actionable information.
`
`STOOL DNA SGLATION
`
`DMNASTABILITY TECHNOLOGY
`
`DNA BIOMARKER DETECTION
`
`ALGORITHM
`
`MATHEMATICAL
`
`POWERFUL
`
`0000 86
`
`GeneoscopyExhibit 1079, Page 7
`
`Geneoscopy Exhibit 1079, Page 7
`
`